Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Cim Investment Management Inc.

Cim Investment Management Inc. trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,936 shares of the medical instruments supplier’s stock after selling 109 shares during the quarter. Cim Investment Management Inc.’s holdings in Becton, Dickinson and were worth $1,200,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Prospera Financial Services Inc raised its position in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Prospera Financial Services Inc now owns 9,245 shares of the medical instruments supplier’s stock worth $2,249,000 after purchasing an additional 41 shares during the period. Lowe Brockenbrough & Co. Inc. grew its holdings in Becton, Dickinson and by 0.4% in the 1st quarter. Lowe Brockenbrough & Co. Inc. now owns 10,613 shares of the medical instruments supplier’s stock worth $2,581,000 after buying an additional 42 shares in the last quarter. Profund Advisors LLC grew its holdings in Becton, Dickinson and by 0.8% in the 2nd quarter. Profund Advisors LLC now owns 5,692 shares of the medical instruments supplier’s stock worth $1,384,000 after buying an additional 43 shares in the last quarter. Arjuna Capital grew its holdings in Becton, Dickinson and by 1.2% in the 2nd quarter. Arjuna Capital now owns 3,856 shares of the medical instruments supplier’s stock worth $938,000 after buying an additional 45 shares in the last quarter. Finally, Bowen Hanes & Co. Inc. grew its holdings in Becton, Dickinson and by 0.7% in the 2nd quarter. Bowen Hanes & Co. Inc. now owns 6,803 shares of the medical instruments supplier’s stock worth $1,654,000 after buying an additional 45 shares in the last quarter. 84.25% of the stock is owned by institutional investors.

Shares of BDX traded up $2.89 during mid-day trading on Thursday, reaching $242.73. The company’s stock had a trading volume of 10,551 shares, compared to its average volume of 1,367,665. The business has a fifty day moving average of $250.06 and a 200 day moving average of $248.06. The company has a market cap of $69.71 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.42 and a beta of 0.76. Becton, Dickinson and Company has a 1 year low of $226.15 and a 1 year high of $267.37. The company has a quick ratio of 0.85, a current ratio of 1.23 and a debt-to-equity ratio of 0.65.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Wednesday, August 4th. The medical instruments supplier reported $2.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.30. Becton, Dickinson and had a return on equity of 16.26% and a net margin of 9.72%. The company had revenue of $4.89 billion during the quarter, compared to analyst estimates of $4.51 billion. During the same quarter in the prior year, the company earned $2.20 earnings per share. The company’s revenue for the quarter was up 26.8% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and Company will post 12.9 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 30th. Investors of record on Thursday, September 9th were issued a dividend of $0.83 per share. The ex-dividend date was Wednesday, September 8th. This represents a $3.32 annualized dividend and a dividend yield of 1.37%. Becton, Dickinson and’s dividend payout ratio is 32.55%.

A number of equities analysts have issued reports on the company. SVB Leerink decreased their price target on Becton, Dickinson and from $260.00 to $250.00 and set a “market perform” rating for the company in a research note on Friday, August 6th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “strong sell” rating and set a $208.00 price objective for the company. in a research note on Monday, October 4th. Finally, JPMorgan Chase & Co. lowered Becton, Dickinson and from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $276.93 to $265.00 in a research note on Friday, August 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $266.33.

In other Becton, Dickinson and news, Director Claire Fraser sold 387 shares of the stock in a transaction on Wednesday, August 18th. The shares were sold at an average price of $251.58, for a total transaction of $97,361.46. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Rebecca W. Rimel sold 207 shares of the stock in a transaction on Monday, August 30th. The stock was sold at an average price of $252.00, for a total transaction of $52,164.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,093 shares of company stock valued at $2,330,578. 0.76% of the stock is owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

See Also: Initial Coin Offering (ICO)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.